Sartorius Expands Drug Discovery and Biomanufacturing Deal with NVIDIA

Sartorius, a leading life sciences and bioprocessing company, has expanded its collaboration with NVIDIA, a pioneer in AI-powered computing. This partnership aims to leverage AI technology to enhance drug discovery and biomanufacturing processes.

The Collaboration

Since 2020, Sartorius has integrated NVIDIA’s technology into its instruments, enhancing live-cell imaging and AI assays. The collaboration focuses on developing predictive AI models, particularly for stem cell-derived organoids, to replace animal models in drug discovery and precision medicine.

Expansion Highlights

1. NVIDIA Clara Suite: Sartorius will increase the use of NVIDIA Clara's AI-powered computing platforms and services.

2. Predictive Models: New predictive AI models, tools, and simulations will be developed for various applications, available through the NVIDIA Clara suite and DGX platform.

3. Advanced Technologies: The partnership will explore 3D-bioprinted spheroids, organoids, and synthetic biological pathways designed with Sartorius cell lines to create novel therapies.

Impact on Bioprocessing

The expanded partnership aims to simplify and accelerate biopharma drug discovery and manufacturing, promising technological innovations that benefit both Sartorius customers and patients.

Sartorius and NVIDIA’s enhanced collaboration signifies a step forward in integrating AI with life sciences, potentially revolutionizing drug discovery and biomanufacturing by providing advanced predictive tools and improving efficiency and product quality in the biotech industry.